Latest Report on Vascular Endothelial Growth Factor B – Pipeline Review, H2 2020

Research By Markets adds Market Research Report - Latest Report on Vascular Endothelial Growth Factor B – Pipeline Review, H2 2020

For detailed information: https://www.researchbymarkets.com/report/vascular-endothelial-growth-factor-b-pipeline-review-h2-2020-625957.html

Vascular Endothelial Growth Factor B – Pipeline Review, H2 2020

Summary

According to the recently published report ‘Vascular Endothelial Growth Factor B – Pipeline Review, H2 2020’; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 16 molecules.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) – Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

The report ‘Vascular Endothelial Growth Factor B – Pipeline Review, H2 2020’ outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 5, 6, 3 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR) and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
– The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
– The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
Alteogen Inc
Amgen Inc
Cinnagen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
CSL Ltd
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/625957

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.